Maplight Therapeutics, Inc.’s Quiet Period Will Expire on December 8th (NASDAQ:MPLT)

Maplight Therapeutics’ (NASDAQ:MPLT) quiet period is set to end on Monday, December 8th. Maplight Therapeutics had issued 14,750,000 shares in its public offering on October 27th. The total size of the offering was $250,750,000 based on an initial share price of $17.00. During Maplight Therapeutics’ quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MPLT. Jefferies Financial Group assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. Leerink Partners started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price on the stock. Leerink Partnrs raised Maplight Therapeutics to a “strong-buy” rating in a research note on Friday, November 21st. Zacks Research raised Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Finally, Stifel Nicolaus started coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $31.00.

Maplight Therapeutics Trading Up 8.4%

Maplight Therapeutics stock opened at $18.34 on Friday. Maplight Therapeutics has a one year low of $12.24 and a one year high of $20.86.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.